1157. Clinical Safety, Efficacy, and Pharmacokinetics of Fosmanogepix, a Novel First-in-class Antifungal, in Patients with Renal Insufficiency: Subset Analysis from a Phase 2 Candidemia Trial

BACKGROUND: Fosmanogepix (FMGX) is a first-in-class antifungal agent, with a unique MOA targeting the fungal enzyme Gwt1, and broad-spectrum activity against yeasts and molds, including fungi resistant to other antifungal agents. Patients with candidemia often have underlying renal insufficiency or...

Descripción completa

Detalles Bibliográficos
Autores principales: Bulpa, Pierre, Rahav, Galia, Oren, Ilana, Aoun, Mickaël, Thompson, George R, Pappas, Peter, Kullberg, Bart Jan, Vazquez, Jose A, Barbat, Sara, Wedel, Pamela, Schlamm, Haran T, Hodges, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Poster Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7776851/
http://dx.doi.org/10.1093/ofid/ofaa439.1343

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7776851/
http://dx.doi.org/10.1093/ofid/ofaa439.1343

Ejemplares similares